Literature DB >> 29939484

Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing.

Wenhua Zhou1, Haodong Cui1, Liming Ying2, Xue-Feng Yu1.   

Abstract

A biodegradable two-dimensional (2D) delivery platform based on loading black phosphorus nanosheets (BPs) with Cas9 ribonucleoprotein engineered with three nuclear localization signals (NLSs) at C terminus (Cas9N3) is successfully established. The Cas9N3-BPs enter cells effectively via membrane penetration and endocytosis pathways, followed by a BPs biodegradation-associated endosomal escape and cytosolic releases of the loaded Cas9N3 complexes. The Cas9N3-BPs thus provide efficient genome editing and gene silencing in vitro and in vivo at a relatively low dose as compared with other nanoparticle-based delivery platforms. This biodegradable 2D delivery platform offers a versatile cytosolic delivery approach for CRISPR/Cas9 ribonucleoprotein and other bioactive macromolecules for biomedical applications.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CRISPR/Cas9; black phosphorus; gene silencing; genome editing; two-dimensional materials

Mesh:

Substances:

Year:  2018        PMID: 29939484     DOI: 10.1002/anie.201806941

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  25 in total

Review 1.  Current Advances in Black Phosphorus-Based Drug Delivery Systems for Cancer Therapy.

Authors:  Wenxin Liu; Alideertu Dong; Bing Wang; Han Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-01-15       Impact factor: 16.806

2.  2D layered nanomaterials for therapeutics delivery.

Authors:  Ryan Davis; Richard A Urbanowski; Akhilesh K Gaharwar
Journal:  Curr Opin Biomed Eng       Date:  2021-07-02

3.  Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing.

Authors:  Tuo Wei; Qiang Cheng; Lukas Farbiak; Daniel G Anderson; Robert Langer; Daniel J Siegwart
Journal:  ACS Nano       Date:  2020-07-22       Impact factor: 15.881

4.  Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid.

Authors:  Ami Jo; Veronica M Ringel-Scaia; Dylan K McDaniel; Cassidy A Thomas; Rui Zhang; Judy S Riffle; Irving C Allen; Richey M Davis
Journal:  J Nanobiotechnology       Date:  2020-01-20       Impact factor: 10.435

Review 5.  CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Authors:  Hanan Bloomer; Jennifer Khirallah; Yamin Li; Qiaobing Xu
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

Review 6.  Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.

Authors:  Alesya G Bykonya; Alexander V Lavrov; Svetlana A Smirnikhina
Journal:  Mol Biotechnol       Date:  2022-03-24       Impact factor: 2.695

7.  Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR/Cas9-mediated targeting of a major viral latent protein.

Authors:  Enguo Ju; Tingting Li; Suzane Ramos da Silva; Ashley Markazi; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2021-05-03       Impact factor: 20.693

Review 8.  Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine.

Authors:  Xiaofeng Dai; Pilar Blancafort; Peiyu Wang; Agustin Sgro; Erik W Thompson; Kostya Ken Ostrikov
Journal:  Adv Sci (Weinh)       Date:  2020-04-23       Impact factor: 16.806

9.  Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform.

Authors:  Yongchun Pan; Jingjing Yang; Xiaowei Luan; Xinli Liu; Xueqing Li; Jian Yang; Ting Huang; Lu Sun; Yuzhen Wang; Youhui Lin; Yujun Song
Journal:  Sci Adv       Date:  2019-04-03       Impact factor: 14.136

10.  Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.

Authors:  Piyush K Jain; Justin H Lo; Santosh Rananaware; Marco Downing; Apekshya Panda; Michelle Tai; Srivatsan Raghavan; Heather E Fleming; Sangeeta N Bhatia
Journal:  Nanoscale       Date:  2019-10-31       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.